<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01592708</url>
  </required_header>
  <id_info>
    <org_study_id>12-0622</org_study_id>
    <secondary_id>R01DE005215</secondary_id>
    <nct_id>NCT01592708</nct_id>
  </id_info>
  <brief_title>Study of Anesthesia Techniques to Reduce Nausea and Vomiting After Jaw Corrective Surgery</brief_title>
  <official_title>A Prospective Evaluation of an Anesthesia Protocol to Reduce Post-operative and Post-discharge Nausea and Vomiting in a High Risk Orthognathic Surgery Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a multi-modal anesthesia and pain control
      protocol reduces post-operative and post-discharge nausea and vomiting (PONV and PDNV) in
      patients undergoing upper jaw corrective surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-operative and post-discharge nausea and vomiting (PONV and PDNV) plague post-anesthesia
      and surgical care. This fact remains especially true for the orthognathic surgery (OS)
      population undergoing procedures involving the maxilla. Current data estimate that the
      incidence of PONV for OS patients undergoing surgery involving the maxilla is between 44% and
      68% as compared to 8% to 30% in general surgical populations, despite application of
      conventional therapies. No one has accounted for or addressed this difference in clinical
      outcomes.

      The implications of PONV for both individual health and overall health care system function
      are considerable. For individual patients, PONV can result in dehydration, wound dehiscence,
      intra-oral bleeding with continued swallowing of blood, significant anxiety and agitation
      (particularly for OS patients who often have heavy elastics closing their jaws together after
      surgery), and, in extreme cases, esophageal damage or the risk of pulmonary aspiration.
      Evidence shows fear of PONV overshadows concerns about pain in surgical patients. At the
      health care system level, evidence suggests PONV can significantly increase health care costs
      through prolonged post-anesthesia care unit (PACU) stays and unplanned hospital admissions
      following outpatient procedures. In one seminal study the odds ratio for unplanned admission
      due to vomiting after intended outpatient surgery was 3.4, an alarmingly high figure exceeded
      only by the odds ratios for readmission due to pain or bleeding.

      Established patient-related risk factors for PONV include female gender, tobacco abstinence,
      and history of prior PONV or motion sickness; additional patient factors may include younger
      age, low American Society of Anesthesiologists Physical Status Classification System status,
      anxiety, and a migraine headache history. Known anesthesia technique-related risk factors
      include volatile anesthetic and nitrous oxide use as well as excessive IV opioid
      administration. High dose neuromuscular blockade reversal agents have also been implicated.
      Surgery-related factors include duration of surgery and type of surgery, with OS ranking
      among the high-risk types.

      Because PONV (and PDNV) prevention and treatment for the OS population remain
      under-investigated domains of clinical care, the investigators seek to address this
      deficiency through multi-modal prophylactic therapy. As more OS procedures are performed,
      many on an ambulatory basis, tactics to reduce the high incidence of PONV in this surgical
      population become important to maximize patient safety and satisfaction and to contain costs.

      The investigators' protocol will synthesize several recommendations to reduce risk of PONV.
      Volatile anesthetics and nitrous oxide will be avoided in favor of a total intravenous (IV)
      anesthetic involving propofol, neostigmine will be minimized, hydration goals will be set,
      and opioid sparing analgesics will be utilized. It is recommended that patients at high risk
      for PONV receive combination therapy with prophylactic agents from multiple classes. Among
      those shown to reduce PONV are 5-HT3 receptor antagonists (such as ondansetron), droperidol,
      and dexamethasone. Transdermal (TD) scopolamine is another effective adjunctive therapy to
      reduce PONV. Additionally, the investigators posit that the constant swallowing of small
      amounts of oozing blood and its retention in the stomach following OS contribute to the high
      incidence of PONV and PDNV in the OS population. Thus sub-bacteriostatic doses of
      erythromycin, capitalizing on erythromycin's established properties as a motilin agonist and
      thus a pro-kinetic, will be added to the evidence-based multi-modal regimen. Erythromycin has
      been chosen over metoclopramide due to safety profile and its well-characterized impact on
      gastric motility and even PONV.

      Rescue anti-nausea and anti-emetic therapy will be chosen from several options at the
      discretion of the treating physician. Options that work through several mechanisms have been
      selected based on the Society of Ambulatory Anesthesia Guidelines and on data from a
      randomized, double-blind, placebo-controlled study of over 2000 subjects.

      Anesthesia variables as well as post-operative analgesic regimens are the primary targets of
      the investigators' multimodal regimen. Multimodal therapy has been shown to be superior to
      single agent therapy. One particularly compelling example showed a 98% response rate (no
      PONV) vs 76% among those receiving mono-therapy and 59% receiving routine anesthesia with
      placebo. Despite these reported successes, PONV remains a major problem for patients
      undergoing OS and many other procedures. This study represents one step towards understanding
      and addressing this significant peri-operative problem.

      This proposed study will compare a cohort receiving a multimodal regimen with a retrospective
      control cohort reviewed in an IRB-approved study at the same institution. The investigators'
      re-use of the data adds no risk of harm or disclosure to the control subjects. Utilization of
      this retrospective control has an important advantage over a concurrent control: It allows
      comparison to a group treated at the same institution without the potential introduction of
      bias by alerting practitioners to the extent of the PONV problem in OS. The investigators
      believe that, as the under-recognition of the OS group as high-risk likely contributes to the
      high rate of PONV these patients experience, education of the anesthesia community introduces
      a potential confounding variable. Further, comparing practice &quot;as is&quot; to the proposed
      protocol maximizes generalizability to other institutions. If, as anticipated, significant
      reductions in PONV and PDNV experience are found, prospective randomized trials to tease out
      nuances of contributing factors could be undertaken.

      Potential influencing patient- and surgery-related variables will be collected to allow
      comparison of the two cohorts using logistic regression analyses.

      Even less well understood than PONV is PDNV; additional studies are needed to deepen
      understanding of the risk factors and treatment options for PDNV. A prior study from the
      investigators' institution demonstrated a high incidence of PDNV in the OS population - 43%
      experienced nausea and 23% vomited after discharge in contrast to general reported rates of
      17% PDN and 8% PDV. This study should offer additional insight into PONV's less understood
      counterpart through diary review of patient's self-reported experience of PDNV following
      discharge from direct medical supervision.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative Nausea</measure>
    <time_frame>End of surgery to discharge from hospital</time_frame>
    <description>End of surgery time determined by anesthesia portion of the medical record. PONV to be assessed by review of surgeons' and nurses' notes in the medical record as well as through review of patient diaries. Vomiting constitutes a safety issue and, as such, associated adverse events will be noted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-operative Vomiting</measure>
    <time_frame>End of surgery to discharge from hospital</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>Anesthesia start time to placement of hospital discharge order - average 26 - 28 hours</time_frame>
    <description>Anesthesia start time determined from anesthesia portion of the medical record. Time at which discharge order was placed will serve as time of discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-discharge Nausea</measure>
    <time_frame>1 week from discharge from hospital</time_frame>
    <description>To be assessed based on patient diary completed daily for 1 week following discharge to home from the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-discharge Vomiting</measure>
    <time_frame>1 week post discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">233</enrollment>
  <condition>Post-operative Nausea</condition>
  <condition>Post-operative Vomiting</condition>
  <condition>Nausea Persistent</condition>
  <arm_group>
    <arm_group_label>Antiemetic anesthesia protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Scopolamine 1.5 milligram(mg) patch Propofol infusion remifentanil infusion 250mg erythromycin po for 2 doses Solumedrol 0.625mg IV droperidol 4mg IV Ondansetron Ketorolac 30mg IV ibuprofen 600mg po q6h Fentanyl Hydrocodone/Tylenol po</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antiemetic anesthesia protocol</intervention_name>
    <description>Intervention group consisted of patients undergoing maxillary osteotomy who received an antiemetic protocol designed to provide multimodal antiemetic therapy which have been shown to help prevent and/or treat postoperative nausea, combined with the elimination of anesthetic factors that may contribute to postoperative nausea and vomiting.</description>
    <arm_group_label>Antiemetic anesthesia protocol</arm_group_label>
    <other_name>Scopolamine 1.5 milligram(mg) patch</other_name>
    <other_name>Propofol infusion</other_name>
    <other_name>remifentanil infusion</other_name>
    <other_name>250mg erythromycin po for 2 doses</other_name>
    <other_name>Solumedrol</other_name>
    <other_name>0.625mg IV droperidol</other_name>
    <other_name>4mg IV Ondansetron</other_name>
    <other_name>Ketorolac 30mg IV</other_name>
    <other_name>ibuprofen 600mg po q6h</other_name>
    <other_name>Fentanyl</other_name>
    <other_name>Hydrocodone/Tylenol po</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  15 years old or older

          -  Undergoing elective orthognathic surgery involving a maxillary osteotomy

        Exclusion Criteria:

          -  uncontrolled GERD or hiatal hernia

          -  glaucoma

          -  seizure disorder

          -  COPD

          -  obstructive sleep apnea

          -  chronic kidney disease stage III or greater

          -  known prolonged QT interval (QTc &gt; 460) or the same found incidentally

          -  history of severe constipation

          -  pre-existing chronic nausea or vomiting

          -  allergies or contraindications to protocol medications

          -  patient insistence on inhalational induction of anesthesia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ceib Philllips, PhD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC-Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Silva AC, O'Ryan F, Poor DB. Postoperative nausea and vomiting (PONV) after orthognathic surgery: a retrospective study and literature review. J Oral Maxillofac Surg. 2006 Sep;64(9):1385-97. Review.</citation>
    <PMID>16916674</PMID>
  </reference>
  <reference>
    <citation>Cohen MM, Duncan PG, DeBoer DP, Tweed WA. The postoperative interview: assessing risk factors for nausea and vomiting. Anesth Analg. 1994 Jan;78(1):7-16.</citation>
    <PMID>8267183</PMID>
  </reference>
  <reference>
    <citation>Chung F, Un V, Su J. Postoperative symptoms 24 hours after ambulatory anaesthesia. Can J Anaesth. 1996 Nov;43(11):1121-7.</citation>
    <PMID>8922767</PMID>
  </reference>
  <reference>
    <citation>Peacock JE, Philip BK. Ambulatory anesthesia experience with remifentanil. Anesth Analg. 1999 Oct;89(4 Suppl):S22-7. Review.</citation>
    <PMID>10511074</PMID>
  </reference>
  <reference>
    <citation>Philip BK. Patients' assessment of ambulatory anesthesia and surgery. J Clin Anesth. 1992 Sep-Oct;4(5):355-8.</citation>
    <PMID>1389187</PMID>
  </reference>
  <reference>
    <citation>Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, Kovac A, Philip BK, Sessler DI, Temo J, Tramèr MR, Watcha M; Department of Anesthesiology, Duke University Medical Center. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg. 2003 Jul;97(1):62-71, table of contents. Review.</citation>
    <PMID>12818945</PMID>
  </reference>
  <reference>
    <citation>Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology. 1992 Jul;77(1):162-84. Review.</citation>
    <PMID>1609990</PMID>
  </reference>
  <reference>
    <citation>Watcha MF, White PF. Post-operative nausea and vomiting: do they matter? Eur J Anaesthesiol Suppl. 1995 May;10:18-23.</citation>
    <PMID>7641638</PMID>
  </reference>
  <reference>
    <citation>Gold BS, Kitz DS, Lecky JH, Neuhaus JM. Unanticipated admission to the hospital following ambulatory surgery. JAMA. 1989 Dec 1;262(21):3008-10.</citation>
    <PMID>2810644</PMID>
  </reference>
  <reference>
    <citation>Koivuranta M, Läärä E, Snåre L, Alahuhta S. A survey of postoperative nausea and vomiting. Anaesthesia. 1997 May;52(5):443-9.</citation>
    <PMID>9165963</PMID>
  </reference>
  <reference>
    <citation>Macario A, Weinger M, Carney S, Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg. 1999 Sep;89(3):652-8.</citation>
    <PMID>10475299</PMID>
  </reference>
  <reference>
    <citation>Gan T, Sloan F, Dear Gde L, El-Moalem HE, Lubarsky DA. How much are patients willing to pay to avoid postoperative nausea and vomiting? Anesth Analg. 2001 Feb;92(2):393-400.</citation>
    <PMID>11159239</PMID>
  </reference>
  <reference>
    <citation>Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999 Sep;91(3):693-700.</citation>
    <PMID>10485781</PMID>
  </reference>
  <reference>
    <citation>Fero KE, Jalota L, Hornuss C, Apfel CC. Pharmacologic management of postoperative nausea and vomiting. Expert Opin Pharmacother. 2011 Oct;12(15):2283-96. doi: 10.1517/14656566.2011.598856. Epub 2011 Jul 15. Review.</citation>
    <PMID>21756206</PMID>
  </reference>
  <reference>
    <citation>Gan TJ, Meyer TA, Apfel CC, Chung F, Davis PJ, Habib AS, Hooper VD, Kovac AL, Kranke P, Myles P, Philip BK, Samsa G, Sessler DI, Temo J, Tramèr MR, Vander Kolk C, Watcha M; Society for Ambulatory Anesthesia. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2007 Dec;105(6):1615-28, table of contents.</citation>
    <PMID>18042859</PMID>
  </reference>
  <reference>
    <citation>Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, Zernak C, Danner K, Jokela R, Pocock SJ, Trenkler S, Kredel M, Biedler A, Sessler DI, Roewer N; IMPACT Investigators. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004 Jun 10;350(24):2441-51.</citation>
    <PMID>15190136</PMID>
  </reference>
  <reference>
    <citation>Tramèr MR, Fuchs-Buder T. Omitting antagonism of neuromuscular block: effect on postoperative nausea and vomiting and risk of residual paralysis. A systematic review. Br J Anaesth. 1999 Mar;82(3):379-86.</citation>
    <PMID>10434820</PMID>
  </reference>
  <reference>
    <citation>Fortney JT, Gan TJ, Graczyk S, Wetchler B, Melson T, Khalil S, McKenzie R, Parrillo S, Glass PS, Moote C, Wermeling D, Parasuraman TV, Duncan B, Creed MR. A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups. Anesth Analg. 1998 Apr;86(4):731-8.</citation>
    <PMID>9539593</PMID>
  </reference>
  <reference>
    <citation>Kranke P, Morin AM, Roewer N, Wulf H, Eberhart LH. The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg. 2002 Jul;95(1):133-43, table of contents.</citation>
    <PMID>12088957</PMID>
  </reference>
  <reference>
    <citation>Apfel CC, Zhang K, George E, Shi S, Jalota L, Hornuss C, Fero KE, Heidrich F, Pergolizzi JV, Cakmakkaya OS, Kranke P. Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis. Clin Ther. 2010 Nov;32(12):1987-2002. doi: 10.1016/j.clinthera.2010.11.014. Review. Erratum in: Clin Ther. 2010 Dec;32(14):2502.</citation>
    <PMID>21118734</PMID>
  </reference>
  <reference>
    <citation>Itoh Z, Nakaya M, Suzuki T, Arai H, Wakabayashi K. Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. Am J Physiol. 1984 Dec;247(6 Pt 1):G688-94.</citation>
    <PMID>6507625</PMID>
  </reference>
  <reference>
    <citation>Kopp VJ, Mayer DC, Shaheen NJ. Intravenous erythromycin promotes gastric emptying prior to emergency anesthesia. Anesthesiology. 1997 Sep;87(3):703-5.</citation>
    <PMID>9316982</PMID>
  </reference>
  <reference>
    <citation>Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P; International Consensus Upper Gastrointestinal Bleeding Conference Group. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med. 2010 Jan 19;152(2):101-13. doi: 10.7326/0003-4819-152-2-201001190-00009.</citation>
    <PMID>20083829</PMID>
  </reference>
  <reference>
    <citation>Barkun AN, Bardou M, Martel M, Gralnek IM, Sung JJ. Prokinetics in acute upper GI bleeding: a meta-analysis. Gastrointest Endosc. 2010 Dec;72(6):1138-45. doi: 10.1016/j.gie.2010.08.011.</citation>
    <PMID>20970794</PMID>
  </reference>
  <reference>
    <citation>Habib AS, Gan TJ. The effectiveness of rescue antiemetics after failure of prophylaxis with ondansetron or droperidol: a preliminary report. J Clin Anesth. 2005 Feb;17(1):62-5.</citation>
    <PMID>15721732</PMID>
  </reference>
  <reference>
    <citation>Scuderi PE, James RL, Harris L, Mims GR 3rd. Multimodal antiemetic management prevents early postoperative vomiting after outpatient laparoscopy. Anesth Analg. 2000 Dec;91(6):1408-14.</citation>
    <PMID>11093990</PMID>
  </reference>
  <reference>
    <citation>Phillips C, Blakey G 3rd. Short-term recovery after orthognathic surgery: a medical daily diary approach. Int J Oral Maxillofac Surg. 2008 Oct;37(10):892-6. doi: 10.1016/j.ijom.2008.07.005. Epub 2008 Sep 2.</citation>
    <PMID>18768296</PMID>
  </reference>
  <reference>
    <citation>Lu CW, Jean WH, Wu CC, Shieh JS, Lin TY. Antiemetic efficacy of metoclopramide and diphenhydramine added to patient-controlled morphine analgesia: a randomised controlled trial. Eur J Anaesthesiol. 2010 Dec;27(12):1052-7. doi: 10.1097/EJA.0b013e32833f53b8.</citation>
    <PMID>20829700</PMID>
  </reference>
  <reference>
    <citation>Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs. 2000 Feb;59(2):213-43. Review.</citation>
    <PMID>10730546</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2012</study_first_submitted>
  <study_first_submitted_qc>May 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2012</study_first_posted>
  <results_first_submitted>July 14, 2014</results_first_submitted>
  <results_first_submitted_qc>July 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 6, 2014</results_first_posted>
  <last_update_submitted>August 15, 2014</last_update_submitted>
  <last_update_submitted_qc>August 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>orthognathic surgery</keyword>
  <keyword>maxillary osteotomy</keyword>
  <keyword>post operative nausea vomiting</keyword>
  <keyword>post discharge nausea vomiting</keyword>
  <keyword>anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Hydrocodone</mesh_term>
    <mesh_term>Droperidol</mesh_term>
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention Cohort</title>
          <description>Patients undergoing maxillary surgery using antiemetic anesthesia protocol</description>
        </group>
        <group group_id="P2">
          <title>Comparison Cohort</title>
          <description>This arm was a retrospective comparison cohort treated at the same institution, managed per provider preference prior to protocol implementation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention Cohort</title>
          <description>This arm was managed perioperatively with the protocol.</description>
        </group>
        <group group_id="B2">
          <title>Comparison Cohort</title>
          <description>This arm was a retrospective comparison cohort treated at the same institution, managed per provider preference prior to protocol implementation.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="137"/>
            <count group_id="B3" value="230"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="17" upper_limit="24"/>
                    <measurement group_id="B2" value="19" lower_limit="17" upper_limit="23"/>
                    <measurement group_id="B3" value="19" lower_limit="17" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-operative Nausea</title>
        <description>End of surgery time determined by anesthesia portion of the medical record. PONV to be assessed by review of surgeons' and nurses' notes in the medical record as well as through review of patient diaries. Vomiting constitutes a safety issue and, as such, associated adverse events will be noted.</description>
        <time_frame>End of surgery to discharge from hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Cohort</title>
            <description>Patients undergoing maxillary surgery using the antiemetic anesthetic protocol</description>
          </group>
          <group group_id="O2">
            <title>Comparison Cohort</title>
            <description>This arm was a retrospective comparison cohort treated at the same institution, managed per provider preference prior to protocol implementation.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Nausea</title>
          <description>End of surgery time determined by anesthesia portion of the medical record. PONV to be assessed by review of surgeons' and nurses' notes in the medical record as well as through review of patient diaries. Vomiting constitutes a safety issue and, as such, associated adverse events will be noted.</description>
          <units>percentage of subjects with PON</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <description>Anesthesia start time determined from anesthesia portion of the medical record. Time at which discharge order was placed will serve as time of discharge.</description>
        <time_frame>Anesthesia start time to placement of hospital discharge order - average 26 - 28 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Cohort</title>
            <description>Patients undergoing maxillary surgery using the antiemetic anesthetic protocol</description>
          </group>
          <group group_id="O2">
            <title>Comparison Cohort</title>
            <description>This arm was a retrospective comparison cohort treated at the same institution, managed per provider preference prior to protocol implementation.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <description>Anesthesia start time determined from anesthesia portion of the medical record. Time at which discharge order was placed will serve as time of discharge.</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" lower_limit="23.5" upper_limit="32.6"/>
                    <measurement group_id="O2" value="28.2" lower_limit="23.5" upper_limit="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-discharge Nausea</title>
        <description>To be assessed based on patient diary completed daily for 1 week following discharge to home from the hospital</description>
        <time_frame>1 week from discharge from hospital</time_frame>
        <population>This analysis only possible with patients who successfully completed the post-discharge diary. Therefore, the participant number differs from the total patients enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Cohort</title>
            <description>Patients undergoing maxillary surgery using the antiemetic anesthetic protocol who completed the post-discharge diary.</description>
          </group>
          <group group_id="O2">
            <title>Comparison Cohort</title>
            <description>This arm was a retrospective comparison cohort treated at the same institution, managed per provider preference prior to protocol implementation, who completed the post-discharge diary</description>
          </group>
        </group_list>
        <measure>
          <title>Post-discharge Nausea</title>
          <description>To be assessed based on patient diary completed daily for 1 week following discharge to home from the hospital</description>
          <population>This analysis only possible with patients who successfully completed the post-discharge diary. Therefore, the participant number differs from the total patients enrolled.</population>
          <units>percentage of subjects with PDN</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Post-operative Vomiting</title>
        <time_frame>End of surgery to discharge from hospital</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Cohort</title>
            <description>Patients undergoing maxillary surgery using the antiemetic anesthetic protocol</description>
          </group>
          <group group_id="O2">
            <title>Comparison Cohort</title>
            <description>This arm was a retrospective comparison cohort treated at the same institution, managed per provider preference prior to protocol implementation.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Vomiting</title>
          <units>percentage of subjects with POV</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-discharge Vomiting</title>
        <time_frame>1 week post discharge</time_frame>
        <population>This analysis only possible with patients who successfully completed the post-discharge diary. Therefore, the participant number differs from the total patients enrolled.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Cohort</title>
            <description>Patients undergoing maxillary surgery using the antiemetic anesthetic protocol who completed the post-discharge diary</description>
          </group>
          <group group_id="O2">
            <title>Comparison Cohort</title>
            <description>This arm was a retrospective comparison cohort treated at the same institution, managed per provider preference prior to protocol implementation, who completed the post-discharge diary</description>
          </group>
        </group_list>
        <measure>
          <title>Post-discharge Vomiting</title>
          <population>This analysis only possible with patients who successfully completed the post-discharge diary. Therefore, the participant number differs from the total patients enrolled.</population>
          <units>percentage of subjects with PDV</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intervention Cohort</title>
          <description>Patients undergoing maxillary surgery using the antiemetic anesthesia protocol</description>
        </group>
        <group group_id="E2">
          <title>Comparison Cohort</title>
          <description>This arm was a retrospective comparison cohort treated at the same institution, managed per provider preference prior to protocol implementation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jay Anderson, PI</name_or_title>
      <organization>UNC Chapel Hill</organization>
      <phone>919-966-5136</phone>
      <email>janderson@aims.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

